MRI Studies Looking For Clues To Alzheimer’s And Dementia May Have Been Unreliable

A doctor shows the tablet to the senior female patient

A study which was published in the journal Nature found that by studying M.R.I. data from about 50,000 people searching for clues between brain structure and complex psychological traits in groups with different numbers of subjects, thousands of patients must be included for the study to be reliably replicated.  This threw cold water on a number of recent studies done looking for clues in M.R.I.s to solve how diseases develop, looking at anything from autism to Alzheimer’s disease, because they typically only focused on a handful of M.R.I.s.  Researchers from The School of Medicine at Washington University, St. Louis and colleagues located elsewhere noted that researchers across the globe are increasingly using magnetic resonance imaging, or M.R.I., to try and find links between what is seen on an M.R.I. like cortical thickness or patterns of connection, and complicated psychological traits such as cognitive ability or mental-health conditions.  These brain-association studies are looking to unlock clues to what causes mental health and dementia.  The researchers concluded that studies done to date have been too small (many just had a few dozen participants) and suggested that there needed to be at least 1,000 participants for the studies to be considered valid.  This is problematic because M.R.I. machines typically cost about $1,000 per hour to operate.  Journals historically have preferred surprising correlations to findings of no correlation, a phenomenon known as publication bias.  “The paradoxical effect is that the answer that’s the most wrong gets published if you use a small sample,” said Nico Dosenback, an associate professor of neurology at Washington University, as well as an author of the Nature study.

50 Year Anniversary Of War On Cancer

A microscopic look at Alzheimer’s Disease

It was fifty years ago when President Richard Nixon declared a war against cancer when he signed the National Cancer Act while simultaneously increasing funding for cancer research.  At the time, President Nixon said if we could put a man on the moon in eight years, we should be able to do the same with curing cancer.  Unfortunately, it’s easier said than done.  About 600K Americans still die from cancer each year and we are a long ways from finding an outright cure.  However, that’s not to say that progress hasn’t been made.  Over the past 50 years, death rates dropped by 70% for childhood cancers, 56% for colorectal cancer and 39% for female breast cancer, according to the American Cancer Society.  Sadly, painful cancers like pancreatic cancer and glioblastoma—a horrible kind of brain cancer—remain nearly as deadly as they were during Nixon’s rein.

https://www.usatoday.com/story/news/2021/12/23/cancer-war-screening-genetics/6430979001/?gnt-cfr=1

COVID Impact On The Brain May Last Forever

As many as 1 in 3 COVID-19 survivors experience a mental health or neurological disorder within six months of the coronavirus infection, according to a major large-scale study reported in The Lancet Psychiatry.  About 34% of those study had been diagnosed with a neurological or mental health disorder following their bout with COVID.  For nearly 13% of these patients, it was the first time they had received such a diagnosis.  Unfortunately, the symptoms have not gone away for many and may be permanent (AARP Bulletin May 21, P6).

COVID Impact On The Brain May Last Forever : By Derek Baine

We have written repeatedly on our blog about the importance of proper nutrition, social interaction and exercise is key to keeping the mind and body healthy for seniors.  A new study from Arizona State University Edison College of Nursing and Health Innovation had participants either ride a stationary bike or do stretching exercise for six months.  Those who took part in the regular exercise program had significantly less memory loss than those who don’t follow a particular exercise regimen.  The results were published in the Journal of Alzheimer’s disease.

Monterey